Skip to main content

Michael L. Freeman, Ph.D.

  • Professor of Radiation Oncology
  • Professor of Radiology and Radiological Sciences

Phone

615-322-3606

Email

michael.freeman@Vanderbilt.Edu
Vanderbilt Department of Radiation Oncology
Medical Center North, E-1200
Nashville, TN 37232

Michael L. Freeman, Ph.D.

  • Professor of Radiation Oncology
  • Professor of Radiology and Radiological Sciences

615-322-3606

michael.freeman@Vanderbilt.Edu

Vanderbilt Department of Radiation Oncology
Medical Center North, E-1200
Nashville, TN 37232

Profile

Education

  • Ph.D., Colorado State University, Fort Collins, Colorado (1978)
  • B.S., Colorado State University, Fort Collins, Colorado (1974)

Research Emphasis

Drug Discovery/Radiation Sensitizers, Development of novel compounds that target tumor angiogenesis, Nrf2/Keap1 in cancer and inflammation.

Research Description

Radiation Oncology leverages cutting edge advancements in physics and engineering for the treatment of cancer. Co-registration of diagnostic data sets into a coherent 3D-treatment plan allows individualized precision tumor targeting. Radiation oncology has the potential to provide outstanding personalized cancer treatment. However, cancer cell radioresistance and normal tissue injury represent two important limitations that reduce the ability of ionizing radiation to provide local/regional control of tumor growth. To addresses these limitations our laboratory initiated a cancer drug discovery program that seeks to develop efficacious radiation sensitizers. Two-indol-3-yl-methylenequinuclidin-3-ols and 5-((N-benzyl-1H-indol-3-yl)-methylene)pyrimidine-2,4,6(1H,3H,5H) trione have been synthesized and are currently being evaluated using defined DNA substrates, cell-based and murine mouse models. Elucidating the underlying mechanisms that drive the pathophysiology of normal tissue injury produced by ionizing radiation is also a focus of this laboratory. A comprehensive approach is used that encompasses well defined biochemical assays, cell-based assays such as transcriptome profiling, and GEMMs.


Publications

Have any questions? Contact Us 1-877-936-8422 for more information